Roles
- Associate Professor of Clinical Medicine
-
Biography
Dr. Baidal completed Internal Medicine Residency at Jackson Memorial Hospital, University of Miami in 2012. This was followed by a clinical and research fellowship in Endocrinology, Diabetes and Metabolism at BIDMC, Harvard Medical School, in 2015. After completion of his fellowship training, he returned to the Diabetes Research Institute, University of Miami. In his current faculty position, Dr. Baidal is the Center Director for Type 1 Diabetes TrialNet at the University of Miami and a member of the NIDDK funded Collaborative Islet Transplantation Registry Steering Committee and Co-Chair of the Data Elements Committee. Dr. Baidal serves as PI/Co-PI in multiple T1D clinical trials including pancreatic beta cell replacement strategies, TrialNet prevention trials and early intervention trials testing drug and cell therapies aimed at preventing loss of ß-cell function. His clinical focus centers on the management of T1D and type 2 diabetes and the use of advanced diabetes technologies including continuous glucose monitoring devices, smart insulin pens, and hybrid closed loop systems. -
Education & Training
Education
-
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Articles & News
Disclaimer:
Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 13 clinical trials.
-
The primary objective is to evaluate the effect of three doses of Diamyd compared to placebo in terms of (1) beta cell function; and (2) glycemic control in adolescents and adults recently diagnosed with type 1 diabetes (T1D), who carry the human leukocyte antigen (HLA) DR3-DQ2 haplotype and have antibodies against GAD65.The total duration of study participation will be approximately 26 months.
- Principal Investigator: David Baidal
- Study Phase: TBD
- Enrollment Status: Closed
-
This phase 2 trial is a double-blind, randomized, placebo-controlled clinical trial in male and female adolescent and adult participants (ages 12-35 years) with newly diagnosed Stage 3 T1D (within 100 days of diagnosis). The primary objective of this study is to evaluate the efficacy of subtype-selective Janus kinase (JAK) inhibitors in the preservation of cell function in participants with recent onset Stage 3 T1D (diagnosed within 100 days).
- Principal Investigator: David Baidal
- Study Phase: TBD
- Enrollment Status: Open
-
Teplizumab (also known as PRV-031, hOKT3?1 [Ala-Ala], and MGA031) is a humanized monoclonal antibody (mAb) that binds to the CD3-e epitope of the T cell receptor. Teplizumab is being investigated for the prevention of type 1 diabetes (T1D) in people at high risk for developing T1D and for the treatment of patients with newly diagnosed T1D.The PRV-031-001 (PROTECT) study, is a Phase 3, randomized, double-blind, placebo-controlled multicenter, multinational study enrolling approximately 300 participants aged 8 to 17 years with newly diagnosed T1D. The participants are required to receive 2 courses of treatment with either teplizumab (N=200) or placebo (N=100); the duration of the study is 18 months (78 weeks).The current study (PRV-031-003) is a non-interventional extension to the PROTECT study, designed to continue to collect long-term safety and other clinical data for an additional 42 months in participants who have completed the PROTECT study.
- Principal Investigator: David Baidal
- Study Phase: Phase III
- Enrollment Status: Closed
-
Phase 3 Randomized Double-Blind Multinational Placebo-Controlled Study to Evaluate Efficacy and Safety of Teplizumab, a Humanized FcR Non-Binding Anti-CD3 Monoclonal Antibody, in Children and Adolescents With Newly Diagnosed Type 1 Diabetes
- Principal Investigator: David Baidal
- Study Phase: Phase 3
- Enrollment Status: Closed
-
The study is a two-arm, multicenter, double-blinded clinical trial testing sequential therapy with rituximab-pvvr followed by abatacept versus rituximab-pvvr alone in new onset T1D.
- Principal Investigator: David Baidal
- Study Phase: Phase II
- Enrollment Status: Open
-
Participants will receive hydroxychloroquine or placebo andclose monitoring for progression to Stage 2 (abnormal glucosetolerance) or Stage 3 (clinically overt) T1D.
- Principal Investigator: David Baidal
- Study Phase: Phase II
- Enrollment Status: Closed
-
A Pilot, Safety and Feasibility Trial of High-Dose Omega-3 Fatty Acids and High-Dose Cholecalciferol (Vitamin D) Supplementation in Type 1 Diabetes
- Principal Investigator: David Baidal
- Study Phase: Phase 1/Phase 2
- Enrollment Status: Closed
-
This is a double-blinded, multicenter,randomized, placebo controlled trial to determine whether treatment of subjects at risk for diabetes with Abatacept results in delay or prevention of abnormal glucose tolerance.
- Principal Investigator: David Baidal
- Study Phase: Phase II
- Enrollment Status: Closed
-
Myfortic® Monotherapy to Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- Principal Investigator: David Baidal
- Study Phase: N/A
- Enrollment Status: Closed
-
The CITR goals are: To develop and implement standards for reporting islet/beta cell transplants and their outcome. To collect and compile data on all islet/beta cell transplants in human recipients performed in North America, as well as some European and Australian centers. To increase the safety of islet/beta cell transplantation by distributing electronically the pertinent information of submitted serious adverse event reports to all participating clinical centers in a timely fashion. To perform scientific analysis on islet/beta cell transplant data, with particular emphasis on: Safety of islet/beta cell transplant product and procedure and protocolregulated treatment products Number of islet/beta cell transplants and retransplants performed, categorized by transplant institution, donor tissue source and handling, recipient category, transplant technique and site, and recipient treatment protocols Efficacy of islet/beta cell transplants as defined by standardized outcome measures and as determined by donor factors, recipient demographics, donorrecipient matching, islet/beta cell processing and product characteristics, transplant technique and site, recipient treatment, and posttransplant events To communicate comprehensive and current information on islet/beta cell transplantation to transplant institutions, the diabetes and general health care community, and the interested general public via the CITR web site (http://www.citregistry.org), publications, and presentations. To stimulate prospective and retrospective studies on emerging issues of importance.
- Principal Investigator: David Baidal
- Study Phase: N/A
- Enrollment Status: Open
-
Primary Objective:To assess the safety and tolerability of GNTI-122 with and without rapamycin in adult participants with recently diagnosed T1DSecondary Objective:To assess cellular kinetics (CK) of GNTI-122 with and without rapamycin in adult participants with recently diagnosed T1D
- Principal Investigator: David Baidal
- Study Phase: TBD
- Enrollment Status: Open
-
SAB-142 is a preparation of purified fully human polyclonal anti-thymocyte globulin (ATG) immunoglobulin G (IgG) and is being developed as a disease -modifying therapeutic agent to delay the onset and progression of T1D. As a fully human ATG IgG, SAB-142 is expected to combine the beneficial effects of Thymoglobulin with a more favourable safety profile.This study will evaluate the efficacy, safety and tolerability of SAB-142 in patients with Stage 3 NOT1D.Primary Objective (Part A):To evaluate 2 dose levels of SAB-142 in order to facilitate the first age step-down.Primary Objective (Part B):To determine whether SAB142 slows the loss of β cells and preserves β cell function over 12 months in participants with Stage 3 NOT1D.
- Principal Investigator: David Baidal
- Study Phase: TBD
- Enrollment Status: Open
-
This study is a Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-103. The study consists of an approximately 208-day treatment study (up to 28 days for screening, 90 days for dosing and evaluations; and 90 days post-dosing evaluation).Participant ages 12-35 (inclusive) with Stage 3 recent-onset Type 1 Diabetes (T1D) will be screened up to 28 days prior to enrollment into the study.Study drug will be administered by IV infusion over approximately 2-4 hours using a graduated rate of infusion
- Principal Investigator: David Baidal
- Study Phase: TBD
- Enrollment Status: Open